K65.4 Sclerosing mesenteritis

Name of the Condition

• Common name(s): Sclerosing mesenteritis
• Medical term: Sclerosing mesenteritis

Summary

Sclerosing mesenteritis is a rare inflammatory condition affecting the mesentery, the tissue that attaches the intestines to the abdominal wall. It involves fibrosis (scarring) and inflammation of the mesenteric fat, which can lead to abdominal pain, mass formation, or bowel obstruction. The condition may be localized or involve broader mesenteric regions and often requires imaging and histologic evaluation for diagnosis.

Causes

The exact cause of sclerosing mesenteritis is not fully understood, but it is thought to involve an abnormal immune response or inflammatory process targeting the mesenteric fat. Associations have been noted with prior abdominal surgery, infections, autoimmune disorders, or malignancies, though a direct causal link remains unproven. Some cases may occur without identifiable triggers.

Risk Factors

• Prior abdominal surgery or trauma
• Autoimmune conditions (e.g., systemic lupus erythematosus)
• Malignancies (e.g., lymphoma, pancreatic cancer)
• Inflammatory bowel disease
• Certain medications (e.g., beta-blockers, methysergide)
• Idiopathic (no clear cause)

Symptoms

• Chronic or intermittent abdominal pain, often localized to the umbilical region
• Palpable abdominal mass
• Nausea, vomiting, or bloating
• Unintentional weight loss
• Diarrhea or constipation
• Fatigue or malaise

Diagnosis

Diagnosis typically involves a combination of imaging (e.g., CT scan, MRI) to identify mesenteric thickening or masses, and histologic confirmation via biopsy. Blood tests may show elevated inflammatory markers (e.g., ESR, CRP), but these are nonspecific. Differential diagnosis includes malignancy, infection, or other inflammatory conditions, requiring careful evaluation.

Treatment Options

Treatment is tailored to symptom severity and underlying factors. Mild cases may require observation or anti-inflammatory medications (e.g., corticosteroids). Severe symptoms or complications (e.g., bowel obstruction) may necessitate surgery. Immunosuppressants or tamoxifen are sometimes used for refractory cases. Addressing associated conditions (e.g., malignancy) is critical when present.

Prognosis and Follow-Up

Prognosis varies; many patients experience stable or slowly progressive disease, but complications like bowel obstruction or malnutrition can occur. Regular follow-up with imaging and clinical assessment is recommended to monitor for changes. Long-term outcomes depend on symptom control and response to treatment.

Complications

• Bowel obstruction or ischemia
• Malnutrition or weight loss
• Mesenteric vessel compression
• Increased risk of abdominal surgery due to mass effect
• Rare association with malignancy (e.g., lymphoma)

Lifestyle & Prevention

No specific preventive measures exist due to unknown etiology. Maintaining a balanced diet and managing underlying conditions (e.g., autoimmune disorders) may support overall health. Avoiding unnecessary abdominal trauma or surgery when possible is advisable, though not always feasible.

When to Seek Professional Help

Seek care if experiencing persistent abdominal pain, unexplained weight loss, or new abdominal masses. Urgent evaluation is needed for symptoms of bowel obstruction (e.g., severe pain, vomiting, inability to pass stool/gas) or signs of infection (e.g., fever, chills).

Tips for Medical Coders

Document the clinical context, including imaging findings, biopsy results, and associated conditions (e.g., malignancy, autoimmune disease), to support code assignment. Ensure differentiation from other mesenteric processes (e.g., tumors, infections) through detailed clinical notes. Code K65.4 is specific to sclerosing mesenteritis and should not be used for generalized peritonitis or other peritoneal conditions.